Nadia Sawicka-Gutaj

Nadia Sawicka-Gutaj

Auto-generated profile, based on publicly available information

Nadia Sawicka-Gutaj

Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2015 in Tumor Biology
Verified
Journal Article
Open access
PDF file
NSNadia Sawicka-Gutaj
Nadia Sawicka-Gutaj
JWJoanna Waligórska-Stachura
Joanna Waligórska-Stachura
Mirosław AndrusiewiczMirosław Andrusiewicz
Mirosław Andrusiewicz
MBMaciej Biczysko
Maciej Biczysko
JSJerzy Sowiński
Jerzy Sowiński
MRMarek Ruchała
Marek Ruchała
Nicotinamide phosphorybosiltransferase (NAMPT) plays an important role in the regulation of cellular growth, angiogenesis, and apoptosis in mammalian cells. NAMPT overexpression has been recently found in colorectal, breast, prostatic, gastric, esophageal, pancreatic cancers, and specific NAMPT inhibitors might be adjuvant therapeutic modalities. In this study, we analyzed NAMPT expression in 40 malignant and in 67 benign thyroid tissue samples using qPCR. We also investigated relationships between NAMPT expression and survivin/survivin splicing variants DEx3 and 2B expressions. NAMPT expression was significantly higher in thyroid cancers (P < 0.0001), and it was positively correlated with tumor stage (P = 0.0012; r = 0.493). NAMPT expression was significantly higher in tumors staged pT3 or pT4 (16 cases) than in tumors staged pT1 or pT2 (24 cases) (P = 0.0106). Metastases to the lymph nodes were found in 12 out of 40 cases, and NAMPT expression was higher in the metastatic group (P = 0.0258). Multifocality was not associated with higher NAMPT expression (P = 0.3451). NAMPT expression in thyroid cancers significantly correlated with survivin and with survivin splice variant DEx3 expressions (P < 0.0001; r = 0.624 and P = 0.0239; r = 0.357, respectively). There was no correlation between NAMPT and survivin 2B expressions (P = 0.3508). This is the first study demonstrating NAMPT overexpression in thyroid malignancies using quantitative RT-PCR. Moreover, it shows that NAMPT is upregulated in patients with more advanced tumor stage and metastatic disease which may prove to be clinically relevant. Further studies are needed to explain the role of NAMPT in thyroid cancer biology and the possible use of NAMPT inhibitors in thyroid cancer.

1 July 2014 in Annales d'Endocrinologie
Verified
Journal Article
Closed access
NSNadia Sawicka-Gutaj
Nadia Sawicka-Gutaj
AKAleksandra Klimowicz
Aleksandra Klimowicz
JSJerzy Sowinski
Jerzy Sowinski
RORobert Oleksa
Robert Oleksa
MGMaria Gryczynska
Maria Gryczynska
MRMarek Ruchala
Marek Ruchala

1 March 2013 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
NSNadia Sawicka
Nadia Sawicka
MGMaria Gryczyńska
Maria Gryczyńska
MTMonika Tamborska-Zedlewska
Monika Tamborska-Zedlewska
MRMarek Ruchala
Marek Ruchala
JSJerzy Sowiński
Jerzy Sowiński
Hypothalamic-pituitary-adrenal axis impairment in anorexia nervosa is marked by hypercortisolemia, and psychiatric disorders occur in the majority of patients with Cushing’s syndrome. Here we report a patient diagnosed with anorexia nervosa who also developed Cushing’s syndrome. A 26-year-old female had been treated for anorexia nervosa since she was 17 years old, and also developed depression and paranoid schizophrenia. She was admitted to the Department of Endocrinology, Metabolism, and Internal Medicine with a preliminary diagnosis of Cushing’s syndrome. Computed tomography revealed a 27 mm left adrenal tumor, and she underwent laparoscopic adrenalectomy. She was admitted to hospital 6 months after this procedure, at which time she did not report any eating or mood disorder. This is a rare case report of a patient with anorexia nervosa in whom Cushing’s syndrome was subsequently diagnosed. Diagnostic difficulties were caused by the signs and symptoms presenting in the course of both disorders, ie, hypercortisolemia, osteoporosis, secondary amenorrhea, striae, hypokalemia, muscle weakness, and depression.